


Supplementary Figure

Figure 1. Schematic diagram of analysis workflow for Covid-19 drug re-purposing



Supplementary tables

Table S1. The total list of pathways that are upregulated or downregulated in the comparison of 10 datasets: 8 Covid-19 vs healthy datasets and 2 SARS infected vs healthy datasets

Table S2a. The list of drugs and their targets that interact with SARS-CoV-2

Table S2b. Drugs with MoA retrieved from CMAP

Table S3. The ranked list of drugs that significantly alter the pathways upregulated or downregulated after COVID-19/SARS infection

Table S4. The drugs that significantly alter the pathways upregulated or downregulated after COVID-19/SARS infection, and overlaps with previously published datasets of experimental *in vitro* effectivity against SARS-CoV, MERS-CoV or other coronaviruses

Table S5. The drugs that show increased sensitivity based on alteration of pathways upregulated or downregulated after COVID-19/SARS infection.